Anika Therapeutics Exceeds Earnings Estimates and Updates FY26 Outlook
Anika Therapeutics (ANIK) reported second-quarter results that exceeded both top-line revenue and bottom-line earnings estimates. The company posted non-GAAP EPS of $0.42, surpassing expectations by $0.39, while revenue reached $32.6 million—up 15.5% year-over-year—and beat forecasts by $3.39 million. Anika also reported adjusted EBITDA of $7.1 million and ended the quarter with cash and equivalents totaling $38.4 million. The company updated its fiscal 2026 guidance, signaling continued growth momentum despite broader market uncertainties in healthcare sectors. The strong performance reflects solid demand for Anika’s orthopedic products and effective cost management strategies.
Tickers: $ANIK
Topics: Earnings Non-GAAP EPS Revenue Beat